Marksans Pharma Share Price Rises Over 2% on UK Drug Nod, Q4 FY25 Results in Focus

On Thursday, May 15, 2025, shares of Marksans Pharma rose by 2.18% to an intraday high of ₹243.40. However, by 11:20 AM, the stock had trimmed most of its gains and was trading just 0.08% higher at ₹238. In comparison, the BSE Sensex was down 0.10% at 81,247.08.

Reason Behind the Upward Move

The rise in Marksans Pharma’s share price followed news that its UK-based subsidiary, Relonchem Ltd, received marketing approval for Gabapentin 50 mg/ml oral solution from the UK’s Medicines and Healthcare Products Regulatory Agency (UK MHRA).

Gabapentin is a widely used medicine for treating epilepsy and nerve pain. It works by calming abnormal brain activity that leads to seizures and is also used to relieve nerve pain caused by conditions like diabetes, shingles, or injuries.

Read More, BEML Shares to Trade Ex-Date on May 15: Interim Dividend of ₹10. 

Upcoming Q4 FY25 Results and Dividend Announcement

Marksans Pharma is scheduled to announce its Q4 FY25 results on May 19, 2025. On the same day, the board will also consider recommending a dividend for FY25.

In Q3 FY25, the company posted:

• Revenue: ₹681.8 crore, up 16.3% YoY
• Gross Profit: ₹383.5 crore, up 22.4% YoY
• Gross Margin: Improved to 56.2% due to lower raw material costs and a better product mix.

About Marksans Pharma

Based in Mumbai, Marksans Pharma focuses on developing, manufacturing, and marketing generic medicines worldwide. The company operates FDA- and MHRA-approved facilities in India, the USA, and the UK.

Marksans Pharma continues to expand its global reach with strong regulatory approvals and a diverse medicine portfolio.

Conclusion

Marksans Pharma's latest UK approval highlights its growing global regulatory presence and product expansion. With strong Q3 financials and the upcoming Q4 results and dividend decision, investor sentiment remains optimistic. Continued success in securing international authorisations may further strengthen the company’s position in the global generics market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.         

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.